Economic evaluation of a routine rotavirus vaccination programme in Indonesia

An economic evaluation was undertaken to assess the potential for introducing rotavirus vaccine into Indonesia's National Immunization Program. For a projected birth cohort of 4.2 million children was followed until 5 years of age, a routine rotavirus vaccination programme could potentially avert 488,547 cases of diarrhoea treated in outpatient hospital facilities, 176,375 hospitalizations, and 8148 deaths. Assuming a cost of US$ 14 per vaccine course, the incremental cost-effectiveness ratio would equal US$ 120.46 per disability adjusted life years averted, making routine vaccination highly cost-effective given Indonesia's Gross National Income per capita of US$ 1560. At a cost per vaccine course of US$ 3.79 (societal perspective) or US$ 2.70 (health-care system perspective), routine rotavirus vaccination could be potentially cost-saving in Indonesia.